| Mrs Donielle Lynn Brasure, MPT | |
|
232 Atlantic Ave, Millville, DE 19967-6728 | |
| (302) 539-3110 | |
| (302) 539-7237 |
| Full Name | Mrs Donielle Lynn Brasure |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 23 Years |
| Location | 232 Atlantic Ave, Millville, Delaware |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023100641 | NPI | - | NPPES |
| 1023100641 | Medicaid | DE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | J10001969 (Delaware) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aquaworx | 4082891759 | 9 |
News Archive
Reactions and Democratic push back are beginning to be evident after the release Monday of an insurance industry-sponsored report (.pdf) that warns premiums could wind up costing $4,000 more by the end of decade if a proposed health overhaul is implemented, the Associated Press reports. The report isn't "worth the paper it's written on," AARP Executive Vice President John Rother said. The retiree's association has supported health reform (Alonso-Zaldivar and Werner, 10/12).
The supercomputer Cadmos, installed at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in August of 2009, has bared one of its first fruits: the Laboratory of Multiscale Modeling of Materials has recently developed a computer program the accurately models the complex system of blood flow in the heart for individuals at an unheard-of precision of ten millionths of a meter or ten microns.
Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer (NK) cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies.
Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
In the 1990s, neuroscientists identified a class of drugs that showed promise in the area of stroke. NMDA receptor antagonists could limit damage to the brain in animal models of stroke. But one problem complicated testing the drugs in a clinical setting: the side effects included disorientation and hallucinations.
› Verified 3 days ago
| Provider Name | Aquaworx |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1912204983 PECOS PAC ID: 4082891759 Enrollment ID: O20110606000477 |
News Archive
Reactions and Democratic push back are beginning to be evident after the release Monday of an insurance industry-sponsored report (.pdf) that warns premiums could wind up costing $4,000 more by the end of decade if a proposed health overhaul is implemented, the Associated Press reports. The report isn't "worth the paper it's written on," AARP Executive Vice President John Rother said. The retiree's association has supported health reform (Alonso-Zaldivar and Werner, 10/12).
The supercomputer Cadmos, installed at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in August of 2009, has bared one of its first fruits: the Laboratory of Multiscale Modeling of Materials has recently developed a computer program the accurately models the complex system of blood flow in the heart for individuals at an unheard-of precision of ten millionths of a meter or ten microns.
Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer (NK) cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies.
Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
In the 1990s, neuroscientists identified a class of drugs that showed promise in the area of stroke. NMDA receptor antagonists could limit damage to the brain in animal models of stroke. But one problem complicated testing the drugs in a clinical setting: the side effects included disorientation and hallucinations.
› Verified 3 days ago
| Provider Name | Konlian,o'neill & Associates, P.a. |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1083647515 PECOS PAC ID: 0648408997 Enrollment ID: O20140125000074 |
News Archive
Reactions and Democratic push back are beginning to be evident after the release Monday of an insurance industry-sponsored report (.pdf) that warns premiums could wind up costing $4,000 more by the end of decade if a proposed health overhaul is implemented, the Associated Press reports. The report isn't "worth the paper it's written on," AARP Executive Vice President John Rother said. The retiree's association has supported health reform (Alonso-Zaldivar and Werner, 10/12).
The supercomputer Cadmos, installed at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in August of 2009, has bared one of its first fruits: the Laboratory of Multiscale Modeling of Materials has recently developed a computer program the accurately models the complex system of blood flow in the heart for individuals at an unheard-of precision of ten millionths of a meter or ten microns.
Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer (NK) cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies.
Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
In the 1990s, neuroscientists identified a class of drugs that showed promise in the area of stroke. NMDA receptor antagonists could limit damage to the brain in animal models of stroke. But one problem complicated testing the drugs in a clinical setting: the side effects included disorientation and hallucinations.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Donielle Lynn Brasure, MPT 232 Atlantic Ave, Millville, DE 19967-6728 Ph: (302) 539-3110 | Mrs Donielle Lynn Brasure, MPT 232 Atlantic Ave, Millville, DE 19967-6728 Ph: (302) 539-3110 |
News Archive
Reactions and Democratic push back are beginning to be evident after the release Monday of an insurance industry-sponsored report (.pdf) that warns premiums could wind up costing $4,000 more by the end of decade if a proposed health overhaul is implemented, the Associated Press reports. The report isn't "worth the paper it's written on," AARP Executive Vice President John Rother said. The retiree's association has supported health reform (Alonso-Zaldivar and Werner, 10/12).
The supercomputer Cadmos, installed at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in August of 2009, has bared one of its first fruits: the Laboratory of Multiscale Modeling of Materials has recently developed a computer program the accurately models the complex system of blood flow in the heart for individuals at an unheard-of precision of ten millionths of a meter or ten microns.
Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer (NK) cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies.
Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
In the 1990s, neuroscientists identified a class of drugs that showed promise in the area of stroke. NMDA receptor antagonists could limit damage to the brain in animal models of stroke. But one problem complicated testing the drugs in a clinical setting: the side effects included disorientation and hallucinations.
› Verified 3 days ago
Brianna Seakan, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 38069 Town Center Dr, Millville, DE 19967 Phone: 302-539-3110 | |
Mrs. Lauren Kimberly Nuttle, D.P.T Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 232 Atlantic Ave, Millville, DE 19967 Phone: 302-539-3110 Fax: 302-539-7237 | |
Malisa Marie Ochotnicky, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 38069 Town Center Dr Unit 15, Millville, DE 19967 Phone: 302-539-3110 Fax: 302-539-7237 | |
Nicole E Evans, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 35247 Atlantic Ave Unit 2, Millville, DE 19967 Phone: 443-513-1028 | |
Jeffrey West, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 38069 Town Center Dr Unit 15, Millville, DE 19967 Phone: 302-539-3110 Fax: 302-539-7237 | |
Aquacare Physical Therapy Physical Therapist Medicare: Medicare Enrolled Practice Location: 38069 Town Center Dr Unit 15, Millville, DE 19967 Phone: 302-539-3110 Fax: 302-539-7237 |